Analyst Price Targets — VERA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 19, 2025 12:20 pm | — | Goldman Sachs | $95.00 | $47.69 | TheFly | Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs |
| December 11, 2025 1:21 pm | Laura Chico | Wedbush | $33.00 | $45.42 | TheFly | Vera Therapeutics price target raised to $33 from $23 at Wedbush |
| December 8, 2025 1:34 pm | Gavin Clark-Gartner | Evercore ISI | $97.00 | $45.79 | TheFly | Vera Therapeutics price target raised to $97 from $75 at Evercore ISI |
| December 5, 2025 9:49 am | — | Pivotal Research | $73.00 | $42.61 | StreetInsider | Vera Therapeutics (VERA) PT Raised to $73 at TD Cowen |
| November 28, 2025 11:35 am | — | H.C. Wainwright | $90.00 | $33.33 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Vera Therapeutics (VERA) |
| June 3, 2025 2:03 pm | Greg Harrison | Scotiabank | $65.00 | $30.91 | TheFly | Vera Therapeutics price target raised to $65 from $55 at Scotiabank |
| March 21, 2024 6:01 am | Laura Chico | Wedbush | $34.00 | $42.87 | StreetInsider | Vera Therapeutics (VERA) PT Raised to $34 at Wedbush |
| January 26, 2024 6:47 am | Ryan Deschner | Raymond James | $37.00 | $30.18 | StreetInsider | Raymond James Upgrades Vera Therapeutics (VERA) to Strong Buy |
| December 18, 2023 1:59 pm | Ryan Deschner | Raymond James | $29.00 | $15.84 | Benzinga | Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst |
| January 4, 2023 10:29 am | — | Jefferies | $6.00 | $6.37 | Benzinga | Jefferies Downgrades Vera Therapeutics to Hold, Lowers Price Target to $6 |
Latest News for VERA
Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept…
BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.
Vera Therapeutics is downgraded from 'Strong Buy' to 'Hold' due to intensifying competition in the IgAN space. VERA's atacicept met the primary endpoint in the phase 3 ORIGIN trial, enabling a BLA submission and Priority Review with a PDUFA date of July 7, 2026. Competitive risks are heightened by Otsuka's VOYXACT, which shows superior proteinuria reduction and more convenient dosing.
BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A…
Inventiva (NASDAQ: IVA - Get Free Report) and Vera Therapeutics (NASDAQ: VERA - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of current ratings
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VERA.
U.S. House Trading
No House trades found for VERA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.